Illumina Price Target Increased to $89.00 by Analysts at Janney Montgomery Scott (ILMN)
Equities researchers at Janney Montgomery Scott hoisted their price objective on shares of Illumina (NASDAQ:ILMN) from $86.00 to $89.00 in a research report issued on Wednesday, AnalystRatingsNetwork reports. The firm currently has a “neutral” rating on the stock. Janney Montgomery Scott’s price objective points to a potential downside of 4.60% from the stock’s previous close.
In other Illumina news, SVP Nicholas Naclerio sold 20,000 shares of Illumina stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $90.00, for a total value of $1,800,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link.
Shares of Illumina (NASDAQ:ILMN) opened at 93.29 on Wednesday. Illumina has a 1-year low of $44.78 and a 1-year high of $84.85. The stock has a 50-day moving average of $79.25 and a 200-day moving average of $68.21. The company has a market cap of $11.672 billion and a price-to-earnings ratio of 109.19.
Illumina (NASDAQ:ILMN) last released its earnings data on Monday, October 21st. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.40 by $0.05. The company had revenue of $357.00 million for the quarter, compared to the consensus estimate of $343.42 million. During the same quarter in the previous year, the company posted $0.41 earnings per share. The company’s revenue for the quarter was up 24.9% on a year-over-year basis. Analysts expect that Illumina will post $1.77 EPS for the current fiscal year.
A number of other firms have also recently commented on ILMN. Analysts at Cantor Fitzgerald raised their price target on shares of Illumina from $63.00 to $72.00 in a research note to investors on Wednesday. They now have a “hold” rating on the stock. Separately, analysts at ISI Group raised their price target on shares of Illumina to $85.00 in a research note to investors on Tuesday, October 22nd. They now have a “neutral” rating on the stock. Finally, analysts at Barclays raised their price target on shares of Illumina from $85.00 to $90.00 in a research note to investors on Tuesday, October 22nd. They now have an “overweight” rating on the stock. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $80.79.
Illumina, Inc (NASDAQ:ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.